Pro-Inflammatory Profile of Preeclamptic Placental Mesenchymal Stromal Cells: New Insights into the Etiopathogenesis of Preeclampsia

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Rolfo, Alessandro ^a   Giuffrida, Domenica ^b   Nuzzo, Anna Maria ^b   Pierobon, Daniele ^a,c   Cardaropoli, Simona ^a   Piccoli, Ettore ^a   Giovarelli, Mirella ^a,c   Todros, Tullia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b S ANNA HOSPITAL   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 6; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; OSTEOPONTIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; FETUS WEIGHT; FMS LIKE TYROSINE KINASE 1 GENE; GENE ISOLATION; GENE OVEREXPRESSION; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE MIGRATION INHIBITORY FACTOR GENE; MESENCHYMAL STROMA CELL; MOLECULAR PATHOLOGY; PREECLAMPSIA; PROTEIN ISOLATION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; CHORIONIC GONADOTROPIN; CHORIONIC VILLI; CYTOKINES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MESENCHYMAL STROMAL CELLS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEIN-TYROSINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875098796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059403     Document Type: Article

References (96)

1. Chesley LC, (1985) Diagnosis of preeclampsia. Obstet Gynecol 65: 423-425.
2. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99: 159-167.
3. Redman CW, Sargent IL, (2005) Latest advances in understanding preeclampsia. Science 308: 1592-1594.
4. Roberts JM, Gammill HS, (2005) Preeclampsia: recent insights. Hypertension 46: 1243-1249.
5. Cunningham FG, Lindheimer MD, (1992) Hypertension in pregnancy. N Engl J Med 326: 927-932.
6. Pijnenborg R, Vercruysse L, Verbist L, Van Assche FA, (1998) Interaction of interstitial trophoblast with placental bed capillaries and venules of normotensive and pre-eclamptic pregnancies. Placenta 19: 569-575.
7. Lockwood CJ, Yen CF, Basar M, Kayisli UA, Martel M, et al. (2008) Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol 172: 1571-1579.
8. Sibai B, Dekker G, Kupferminc M, (2005) Pre-eclampsia. Lancet 365: 785-799.
9. Gammill HS, Roberts JM, (2007) Emerging concepts in preeclampsia investigation. Front Biosci 12: 2403-2411.
10. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, et al. (2004) Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22: 649-658.
11. Li C, Zhang W, Jiang X, Mao N, (2007) Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res 330: 437-446.
12. Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, et al. (2006) Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24: 2466-2477.
13. Parolini O, Alviano F, Bergwerf I, Boraschi D, De Bari C,et al. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev 19: 143-154.
14. Croy BA, Chantakru S, Esadeg S, Ashkar AA, Wei Q, (2002) Decidual natural killer cells: key regulators of placental development (a review). J Reprod Immunol 57: 151-168.
15. Boyson JE, Rybalov B, Koopman LA, Exley M, Balk SP, et al. (2002) CD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A 99: 13741-13746.
16. Guimond MJ, Wang B, Croy BA, (1998) Engraftment of bone marrow from severe combined immunodeficient (SCID) mice reverses the reproductive deficits in natural killer cell-deficient tg epsilon 26 mice. J Exp Med 187: 217-223.
17. Croy BA, Ashkar AA, Minhas K, Greenwood JD, (2000) Can murine uterine natural killer cells give insights into the pathogenesis of preeclampsia? J Soc Gynecol Investig 7: 12-20.
18. Reister F, Frank HG, Heyl W, Kosanke G, Huppertz B, et al. (1999) The distribution of macrophages in spiral arteries of the placental bed in pre-eclampsia differs from that in healthy patients. Placenta 20: 229-233.
19. Cardaropoli S, Paulesu L, Romagnoli R, Ietta F, Marzioni D, et al. (2011) Macrophage migration inhibitory factor in fetoplacental tissues from preeclamptic pregnancies with or without fetal growth restriction. Clin Dev Immunol 2012: 639342.
20. Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, et al. (1995) Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 12: 235-243.
21. Chung JY, Song Y, Wang Y, Magness RR, Zheng J, (2004) Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 89: 2484-2490.
22. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
23. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, et al. (2006) Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 291: R1085-1093.
24. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, et al. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88: 2348-2351.
25. Ahmad S, Ahmed A, (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95: 884-891.
26. Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, et al. (2009) Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol 144: 571-579.
27. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
28. Olsen RN, Woelkers D, Dunsmoor-Su R, Lacoursiere DY (2012) Abnormal second-trimester serum analytes are more predictive of preterm preeclampsia. Am J Obstet Gynecol 207: 228 e221-227.
29. Norris W, Nevers T, Sharma S, Kalkunte S, (2011) Review: hCG, preeclampsia and regulatory T cells. Placenta 32Suppl 2: S182-185.
30. King A, Hiby SE, Gardner L, Joseph S, Bowen JM, et al. (2000) Recognition of trophoblast HLA class I molecules by decidual NK cell receptors-a review. Placenta 21 Suppl A: S81-85.
31. Roberts JM, Hubel CA, (1999) Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 354: 788-789.
32. Hubel CA, (1999) Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 222: 222-235.
33. Shibata E, Ejima K, Nanri H, Toki N, Koyama C, et al. (2001) Enhanced protein levels of protein thiol/disulphide oxidoreductases in placentae from pre-eclamptic subjects. Placenta 22: 566-572.
34. Myatt L, Cui X, (2004) Oxidative stress in the placenta. Histochem Cell Biol 122: 369-382.
35. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS (2009) Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta 30 Suppl A: S43-48.
36. Allaire AD, Ballenger KA, Wells SR, McMahon MJ, Lessey BA, (2000) Placental apoptosis in preeclampsia. Obstet Gynecol 96: 271-276.
37. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, et al. (2002) Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 186: 158-166.
38. Leung DN, Smith SC, To KF, Sahota DS, Baker PN, (2001) Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 184: 1249-1250.
39. Crocker IP, Cooper S, Ong SC, Baker PN, (2003) Differences in apoptotic susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to those complicated with preeclampsia and intrauterine growth restriction. Am J Pathol 162: 637-643.
40. Soleymanlou N, Wu Y, Wang JX, Todros T, Ietta F, et al. (2005) A novel Mtd splice isoform is responsible for trophoblast cell death in pre-eclampsia. Cell Death Differ 12: 441-452.
41. Smarason AK, Sargent IL, Starkey PM, Redman CW, (1993) The effect of placental syncytiotrophoblast microvillous membranes from normal and pre-eclamptic women on the growth of endothelial cells in vitro. Br J Obstet Gynaecol 100: 943-949.
42. Caplan AI, Dennis JE, (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98: 1076-1084.
43. Hwang JH, Lee MJ, Seok OS, Paek YC, Cho GJ, et al. (2011) Cytokine expression in placenta-derived mesenchymal stem cells in patients with pre-eclampsia and normal pregnancies. Cytokine 49: 95-101.
44. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA, (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91: 3652-3656.
45. Xu LL, Warren MK, Rose WL, Gong W, Wang JM, (1996) Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 60: 365-371.
46. Sozzani S, Zhou D, Locati M, Rieppi M, Proost P, et al. (1994) Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J Immunol 152: 3615-3622.
47. Dahinden CA, Geiser T, Brunner T, von Tscharner V, Caput D, et al. (1994) Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 179: 751-756.
48. Renaud SJ, Sullivan R, Graham CH, (2009) Tumour necrosis factor alpha stimulates the production of monocyte chemoattractants by extravillous trophoblast cells via differential activation of MAPK pathways. Placenta 30: 313-319.
49. Nautiyal J, Kumar PG, Laloraya M, (2004) Mifepristone (Ru486) antagonizes monocyte chemotactic protein-3 down-regulation at early mouse pregnancy revealing immunomodulatory events in Ru486 induced abortion. Am J Reprod Immunol 52: 8-18.
50. Szarka A, Rigo J, Jr., Lazar L, Beko G, Molvarec A Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11: 59.
51. Gabay C, Kushner I, (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
52. Gotsch F, Romero R, Friel L, Kusanovic JP, Espinoza J, et al. (2007) CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med 20: 777-792.
53. Wang Y, Walsh SW, (1996) TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 32: 157-169.
54. Beckmann I, Efraim SB, Vervoort M, Visser W, Wallenburg HC, (2004) Tumor necrosis factor-alpha in whole blood cultures of preeclamptic patients and healthy pregnant and nonpregnant women. Hypertens Pregnancy 23: 319-329.
55. Todt JC, Yang Y, Lei J, Lauria MR, Sorokin Y, et al. (1996) Effects of tumor necrosis factor-alpha on human trophoblast cell adhesion and motility. Am J Reprod Immunol 36: 65-71.
56. Bauer S, Pollheimer J, Hartmann J, Husslein P, Aplin JD, et al. (2004) Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. J Clin Endocrinol Metab 89: 812-822.
57. Renaud SJ, Postovit LM, Macdonald-Goodfellow SK, McDonald GT, Caldwell JD, et al. (2005) Activated macrophages inhibit human cytotrophoblast invasiveness in vitro. Biol Reprod 73: 237-243.
58. Xu B, Nakhla S, Makris A, Hennessy A TNF-alpha inhibits trophoblast integration into endothelial cellular networks. Placenta 32: 241-246.
59. Simpson H, Robson SC, Bulmer JN, Barber A, Lyall F, (2002) Transforming growth factor beta expression in human placenta and placental bed during early pregnancy. Placenta 23: 44-58.
60. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ, (1999) Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 103: 1641-1650.
61. Todros T, Marzioni D, Lorenzi T, Piccoli E, Capparuccia L, et al. (2007) Evidence for a role of TGF-beta1 in the expression and regulation of alpha-SMA in fetal growth restricted placentae. Placenta 28: 1123-1132.
62. Djurovic S, Schjetlein R, Wisloff F, Haugen G, Husby H, et al. (1997) Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. Clin Genet 52: 371-376.
63. Shaarawy M, El Meleigy M, Rasheed K, (2001) Maternal serum transforming growth factor beta-2 in preeclampsia and eclampsia, a potential biomarker for the assessment of disease severity and fetal outcome. J Soc Gynecol Investig 8: 27-31.
64. Pang ZJ, Zhou JG, Huang LP, (2008) Interleukin-10 may participate in regulating trophoblast invasion in human placentae throughout gestation. Am J Reprod Immunol 60: 19-25.
65. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK,et al. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 176: 710-720.
66. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, et al. (2008) Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453: 1117-1121.
67. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, et al. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109: 2175-2180.
68. Van Campenhout A, Golledge J, (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204: 321-329.
69. Toffoli B, Pickering RJ, Tsorotes D, Wang B, Bernardi S,et al. Osteoprotegerin promotes vascular fibrosis via a TGF-beta1 autocrine loop. Atherosclerosis 218: 61-68.
70. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
71. Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, et al. (2003) Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 88: 5361-5365.
72. Vitoratos N, Lambrinoudaki I, Rizos D, Armeni E, Alexandrou A,et al. Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. Eur J Obstet Gynecol Reprod Biol 154: 141-145.
73. Johnson GA, Burghardt RC, Bazer FW, Spencer TE, (2003) Osteopontin: roles in implantation and placentation. Biol Reprod 69: 1458-1471.
74. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, et al. (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
75. Stenczer B, Rigo J Jr, Prohaszka Z, Derzsy Z, Lazar L, et al. (2012) Plasma osteopontin concentrations in preeclampsia- is there an association with endothelial injury? Clin Chem Lab Med 48: 181-187.
76. Baker PN, Krasnow J, Roberts JM, Yeo KT, (1995) Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 86: 815-821.
77. Hayman R, Brockelsby J, Kenny L, Baker P, (1999) Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Investig 6: 3-10.
78. Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, et al. (1996) Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest 26: 1182-1185.
79. Lyall F, Greer IA, Boswell F, Fleming R, (1997) Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 104: 223-228.
80. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, et al. (2000) Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 183: 1554-1557.
81. Hefler L, Obermair A, Husslein P, Kainz C, Tempfer C, (2000) Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. Acta Obstet Gynecol Scand 79: 77-78.
82. Rajashekhar G, Loganath A, Roy AC, Wong YC, (2002) Expression and localization of angiogenin in placenta: enhanced levels at term over first trimester villi. Mol Reprod Dev 62: 159-166.
83. Rajashekhar G, Loganath A, Roy AC, Wong YC, (2003) Over-expression and secretion of angiogenin in intrauterine growth retardation placenta. Mol Reprod Dev 64: 397-404.
84. Maymo JL, Perez AP, Gambino Y, Calvo JC, Sanchez-Margalet V,et al. Review: Leptin gene expression in the placenta-regulation of a key hormone in trophoblast proliferation and survival. Placenta 32Suppl 2: S146-153.
85. Gearing DP, (1993) The leukemia inhibitory factor and its receptor. Adv Immunol 53: 31-58.
86. Sagawa N, Yura S, Itoh H, Kakui K, Takemura M, et al. (2002) Possible role of placental leptin in pregnancy: a review. Endocrine 19: 65-71.
87. Benian A, Uzun H, Aydin S, Albayrak M, Uludag S, et al. (2008) Placental stem cell markers in pre-eclampsia. Int J Gynaecol Obstet 100: 228-233.
88. Nedeau AE, Bauer RJ, Gallagher K, Chen H, Liu ZJ, et al. (2008) A CXCL5- and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells. Exp Cell Res 314: 2176-2186.
89. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5: e10088.
90. Nishihira J, (2000) Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 20: 751-762.
91. Arcuri F, Cintorino M, Vatti R, Carducci A, Liberatori S, et al. (1999) Expression of macrophage migration inhibitory factor transcript and protein by first-trimester human trophoblasts. Biol Reprod 60: 1299-1303.
92. Arcuri F, Ricci C, Ietta F, Cintorino M, Tripodi SA, et al. (2001) Macrophage migration inhibitory factor in the human endometrium: expression and localization during the menstrual cycle and early pregnancy. Biol Reprod 64: 1200-1205.
93. Todros T, Bontempo S, Piccoli E, Ietta F, Romagnoli R, et al. (2005) Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 123: 162-166.
94. Hirokawa J, Sakaue S, Furuya Y, Ishii J, Hasegawa A, et al. (1998) Tumor necrosis factor-alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J Biochem 123: 733-739.
95. Jelkmann W, (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47: 617-623.
96. Li H, Gu B, Zhang Y, Lewis DF, Wang Y, (2005) Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 26: 210-217.